Advanced Filters
noise

Additional Locations, Massachusetts Clinical Trials

A listing of Additional Locations, Massachusetts clinical trials actively recruiting patient volunteers.

Found 2,363 clinical trials
S Siline Thai

IntelliWell: An AI-Assisted Imaging Platform for Detection and Location of Ultra-Rare Testicular Sperm in Surgical Specimens

This study will help determine whether an AI-assisted microwell platform (IntelliWell) can identify rare sperm cells in testicular samples found to not have sperm by conventional analysis. Instead of discarding testicular tissue which was found to be non-sperm bearing by conventional analysis the testicular tissue will be processed using IntelliWell …

18 years of age Male Phase N/A
H Hannah Lamont, PhD

Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease

An open-labeled, interventional pilot trial, 10 youth with AVP-D and 10 PD matched for age, sex, and BMI will be recruited from Pediatric Endocrinology and Neuroendocrinology at Massachusetts General Hospital and in the community. This study tests the hypothesis that oral estrogen/progestin will stimulate endogenous oxytocin release in control subjects. …

7 - 21 years of age All Phase 0
G Gottfried von Keudell, MD

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

The purpose of this study is to see if the combination of rituximab and venetoclax is effective in treating participants with untreated Marginal Zone Lymphoma (MZL). The names of the study drugs involved in this study are: Venetoclax (a type of inhibitor) Rituximab (a type of antibody)

18 years of age All Phase 2
R Rebecca Davis

Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

RETRIAL is a multi-site observational study of people with Cystic Fibrosis (PWCF) ages 6 and up starting the new triple-therapy modulator (vanzacaftor/tezacaftor/deutivacaftor (VTD)), after having experienced neuropsychiatric events and/or liver injury while taking elexacaftor/tezacaftor/ivacaftor (ETI) that resulted in a modification or discontinuation of standard ETI dosing.

6 years of age All Phase N/A
J Jarrett Hubbard

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

This study is being done to find out if administering CytoGam® after the end of standardly prescribed preventive antiviral treatment can help transplant recipients with a high risk for developing late CMV disease after a liver and/or kidney transplant.

18 - 75 years of age All Phase 4
D Daniel B Kramer, MD

Remote Alert Pathway To Optimize CaRe of Cardiac Implantable Electrical Devices

The Remote Alert Pathway to Optimize Care of Cardiac Implantable Electrical Devices (RAPTOR-CIED) Study is a pragmatic, multi-center, randomized trial with 1:1 patient-level randomization comparing the safety and effectiveness of alert-driven care versus guideline-based care for patients with wireless cardiac implantable electrical devices (CIEDs). The study will be conducted in …

18 years of age All Phase N/A
m medicalinformation@neurenpharma.com

A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

This Phase 3, randomized, double-blind, parallel-group (2-arm), placebo-controlled, multicenter study will evaluate the efficacy and safety of NNZ-2591 compared to placebo in pediatric participants with Phelan- McDermid Syndrome.

3 - 12 years of age All Phase 3
D Daniel Goldenholz, MD PhD

Infrared Photobiomodulation in Humans With Epilepsy

Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited. This study aims to investigate a new treatment that involves using infra-red light. In animals, this treatment has shown promise as a possible way to …

18 years of age All Phase N/A
J Jason Efstathiou, MD, DPhil

Flotufolastat F 18 PET in Men With Very Low PSA Recurrence

The purpose of this study is to assess detection rate of flotufolastat F 18 positron emission tomography (PET) for low prostate specific antigen (PSA) recurrence of prostate cancer (PC) following radical prostatectomy.

18 years of age Male Phase N/A
S Steven Cicero

Assessment of Synaptic Density in MS

The investigators propose to use the novel SV2a-PET ligand, \[F-18\]SDM-8 to assess synaptic density in progressive multiple sclerosis (PMS) (including primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS)), given its improved imaging characteristics and potential for large scale applicability. The specific aims of the study are: Aim …

18 - 60 years of age All Phase 0

Simplify language using AI